A phase II evaluation of liposomal doxorubicin (Doxil) in the treatment of persistent or recurrent squamous cell carcinoma of the cervix
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 10 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 13 Jun 2007 Status changed from in progress to completed.
- 10 Sep 2005 New trial record.